AC Immune(us:ACIU)
1.79
-4.28%
Updated on 2025-04-02
Open:1.85
Close:1.79
High:1.94
Low:1.77
Prev Close:1.87
Volume:213612.00
Turnover:387086.88
Turnover Ratio:0.21%
Shares:100.41M
MarketCap:180.24M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 51 | 28573535 | 28.67% | 14 | 8 | 22 |
| 2024-03-31 | 42 | 28964504 | 29.29% | 10 | 12 | 12 |
| 2023-12-31 | 38 | 29638667 | 29.88% | 10 | 9 | 9 |
| 2023-09-30 | 34 | 15981631 | 18.92% | 3 | 8 | 11 |
| 2023-06-30 | 38 | 16033728 | 17.87% | 4 | 8 | 11 |
| 2023-03-31 | 42 | 14098497 | 16.86% | 5 | 4 | 15 |
| 2022-12-31 | 43 | 14762469 | 17.65% | 9 | 8 | 15 |
| 2022-09-30 | 41 | 14019124 | 16.78% | 5 | 8 | 15 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Bvf Inc/Il | 14571236 | 14.73% | 0 | |
| 2024-03-31 | Avidity Partners Management Lp | 4470000 | 4.52% | 920 | 0.02% |
| 2024-03-31 | Blackrock Inc. | 2541952 | 2.57% | 123932 | 5.13% |
| 2024-03-31 | Redmile Group, Llc | 2007031 | 2.03% | 7031 | 0.35% |
| 2024-03-31 | Morgan Stanley | 1383854 | 1.40% | -373386 | -21.25% |
| 2024-03-31 | Wells Fargo & Company/Mn | 1119703 | 1.13% | -28988 | -2.52% |
| 2024-03-31 | Platinum Investment Management Ltd | 1095026 | 1.11% | -420559 | -27.75% |
| 2024-03-31 | Renaissance Technologies Llc | 515779 | 0.52% | 98200 | 23.52% |
| 2024-03-31 | Deutsche Bank Ag\ | 253375 | 0.26% | 0 | |
| 2024-03-31 | Handelsbanken Fonder Ab | 150000 | 0.15% | 48936 | 48.42% |
About
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Address:EPFL Innovation Park,Building B
Website:http://www.acimmune.com
Market Movers